COX4I2 antibody

Cat.#: 109490

Size:

Special Price 239.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    COX4I2 antibody
  • Documents
  • Description
    COX4I2 Rabbit Polyclonal antibody. Positive IF detected in Hela cells. Positive IHC detected in human ovary tumor tissue. Positive IP detected in HepG2 cells. Positive WB detected in MCF7 cells, A375 cells, HepG2 cells, human brain tissue, human heart tissue, human lung tissue. Observed molecular weight by Western-blot: 17-18 kDa
  • Tested applications
    ELISA, WB, IHC, IF, IP
  • Species reactivity
    Human,Mouse,Rat; other species not tested.
  • Alternative names
    COX IV 2 antibody; COX4 antibody; COX4 2 antibody; COX4B antibody; COX4I2 antibody; COX4L2 antibody; COXIV 2 antibody; dJ857M17.2 antibody
  • Isotype
    Rabbit IgG
  • Preparation
    This antibody was obtained by immunization of COX4I2 recombinant protein (Accession Number: NM_032609). Purification method: Antigen affinity purified.
  • Clonality
    Polyclonal
  • Formulation
    PBS with 0.1% sodium azide and 50% glycerol pH 7.3.
  • Storage instructions
    Store at -20℃. DO NOT ALIQUOT
  • Applications

    Recommended Dilution:

    WB: 1:500-1:5000

    IP: 1:500-1:5000

    IHC: 1:20-1:200

    IF: 1:20-1:200

  • Validations

    IP result of anti-COX4I2 (Catalog No:117309 for IP and Detection) with HepG2 cell lysate.

    IP result of anti-COX4I2 (Catalog No:117309 for IP and Detection) with HepG2 cell lysate.

    MCF7 cells were subjected to SDS PAGE followed by western blot with Catalog No:117309(COX4I2 antibody) at dilution of 1:1000

    MCF7 cells were subjected to SDS PAGE followed by western blot with Catalog No:117309(COX4I2 antibody) at dilution of 1:1000

    IP Result of anti-COX4I2 (IP:Catalog No:117309, 3ug; Detection:Catalog No:117309 1:1000) with HepG2 cells lysate 8000ug.

    IP Result of anti-COX4I2 (IP:Catalog No:117309, 3ug; Detection:Catalog No:117309 1:1000) with HepG2 cells lysate 8000ug.

    Immunohistochemical of paraffin-embedded human ovary tumor using Catalog No:117309(COX4I2 antibody) at dilution of 1:50 (under 10x lens)

    Immunohistochemical of paraffin-embedded human ovary tumor using Catalog No:117309(COX4I2 antibody) at dilution of 1:50 (under 10x lens)

    Immunofluorescent analysis of Hela cells, using COX4I2 antibody Catalog No:117309 at 1:50 dilution and Rhodamine-labeled goat anti-rabbit IgG (red). Blue pseudocolor = DAPI (fluorescent DNA dye).

    Immunofluorescent analysis of Hela cells, using COX4I2 antibody Catalog No:117309 at 1:50 dilution and Rhodamine-labeled goat anti-rabbit IgG (red). Blue pseudocolor = DAPI (fluorescent DNA dye).

  • Background
    COX4I2, also named as COX4L2 and COXIV-2, belongs to the cytochrome c oxidase IV family. It is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport. COXIV(cytochrome c oxidase IV) has two isoforms (isoform 1 and 2). Isoform 1(COX4I1) is ubiquitously expressed and isoform 2 is highly expressed in lung tissues. This antibody was generated against full length COX4I2 protein.
  • References
    • Oliva CR, Markert T, Gillespie GY, Griguer CE. Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas. Oncotarget. 6(6):4330-44. 2015.
    • Oliva CR, Nozell SE, Diers A. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. The Journal of biological chemistry. 285(51):39759-67. 2010.
    • Schneider L, Giordano S, Zelickson BR. Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress. Free radical biology & medicine. 51(11):2007-17. 2011.
    • Hicks S, Labinskyy N, Piteo B. Type II diabetes increases mitochondrial DNA mutations in the left ventricle of the Goto-Kakizaki diabetic rat. American journal of physiology. Heart and circulatory physiology. 304(7):H903-15. 2013.
    • Karampelas T, Argyros O, Sayyad N. GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery. Bioconjugate chemistry. 25(4):813-23. 2014.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"